Evotec gibt Verkauf von API-Productionsanlage and Monacum Partners bekannt » AnlegerPlus

Hamburg, November 5, 2024:
Evotec SE (Frankfurter Wertpaperbörse: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has the sales departments for pharmaceutical industries, the Evotec DS GmbH in Halle (Westf.), and the Monacum Partners GmbH, a subsidiary in Munich Private Equity Gesellschaft, bekannt gegeben. The transaction started in April 2024 with Evotec’s “Priority Reset” initiative. If the soul of the company is profitable, the company compensates for the activities of the external companies and the focus on the primary Wachstumssectors and core competencies aimed at the market.

Evotec DS in Halle (Westphalia) is a specialist manufacturing and production company (CDMO) with extensive expertise in pharmaceutical raw materials, pharmaceutical products and synthetic materials. The third part offers a loss of service portfolio, from the Entwicklung to the Fertigung in kommerziellen Maßstab.

The transaction is very light at Evotec DS, but the own properties are a new peculiarity of verwirklichen. The Vereinbarung ensures that the joint venture and the complete investment of Evotec DS at Monacum Partners de Berg and the Unternehmen as DAPIN GmbH (Deutsche API & Intermediates) continue. The transaction cannot be financed.

Uber Evotec SE
Evotec is a science company with a unique history, a high-quality medicine for research, for working and for the patient who uses his machine. The multimodal platform of the Unternehmens offers a unique innovative combination of technologies, data and science solutions for the research, development and production of first-in-class and best-in-class pharmaceutical products. Evotec offers partnerships and solutions for Pipeline Co-creation of all Top 20 Pharma and more than 800 biotechnology universities, academic institutions and others Akteure des Gesundheitswesens and. Evotec is strategic in a broad spectrum of medically active indications, such as neurology, onkology and respiratory and infectious diseases. Evotecs Ziel has been developing innovative ‘co-owned Pipeline’ therapists and has a portfolio of more than 200 properties and co-ownership of F+E projects from early research in clinical development. The quality amounts to more than 5,000 qualified people for Evotec. The state of affairs in Europe and the US offers high-quality synergistic technologies and services and works as a complementary Exzellenz cluster. Find more information on our homepage www.evotec.com and follow your message on X/Twitter @Evotec and LinkedIn.

Über Monacum Partners
Monacum Partners is a Munich-based private equity company engaged in the strategic redesign of Unternehmen in Europe. In the middle of Monacum Partners’ strategy, the company of the Unternehmen has no longer managed to carry out the operation, but the employee could be scaffolded. The portfolio solutions were developed by the Monacum Partners team member, allowing a turnaround technology to be effectively deployed and integrated with the current system. More information can be found belowwww.monacumpartners.com.

Zukunftsbezogene Aussagen
This press conference has had a great influence on the first impression, which attracts attention and the note of Evotecs working papers. Worter wie “erwarten”, “annehmen”, “schätzen”, “beabsichtigen”, “können”, “planen”, “potenziell”, “sollen”, “abzielen”, “würde”, as well as Abwandlungen dieser Wörter and ähnliche became Used, a zukunftsbezogene Aussagen to identify. Solche Aussagen schließen Comments op Evotecs Erwartungen für Umsätze, Konzern-EBITDA und unverpartnerte F+E-Aufwendungen ein. These cuts are based on the information, the Evotec zum Zeitpunkt der Aussage zugänglich were, anyway auf Erwartungen and Annahmen, the Evotec zu diesem Zeitpunkt for angemessen erachtet hat. The guideline values ​​that exist can no longer be stated with certainty. These excessive risks and risks on one of the Annahmen and Schätzungen, which are inherent in insecurity and independence, can prevent the control from lying by Evotec. Evotec has not used the lighting necessary to perform the display of Evotec in the background or to make a new start, to use the wiring or the stand, or to perform or activate them in order to revise them.

For more information, please read:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
[email protected]

Resourse

Susanne Kreuter
VP Head of Strategic Marketing
[email protected]